Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;34(6):e70153.
doi: 10.1002/pro.70153.

Molecular characterization of a synthetic neutralizing antibody targeting p67 of Theileria parva

Affiliations

Molecular characterization of a synthetic neutralizing antibody targeting p67 of Theileria parva

Shane Miersch et al. Protein Sci. 2025 Jun.

Abstract

The Theileria parva sporozoite surface antigen p67 is a target of the bovine humoral immune response that generates antibodies capable of providing protection against subsequent infection. As a result, p67 has been the subject of efforts aimed at the development of an anti-sporozoite subunit vaccine. Previous studies have identified neutralizing epitopes in the N- and C-terminal regions of the full-length protein and shown that immunization with a C-terminal fragment of p67 (p67C) alone is capable of eliciting protection. To identify additional neutralizing epitopes in p67C, selections were conducted against it using a phage-displayed synthetic antibody library. An antibody that neutralized the sporozoite in vitro was identified, and the crystal structure of a Fab:peptide complex was elucidated. Mutagenesis studies aimed at validating and further characterizing the Fab:peptide interaction identified critical residues involved in binding and neutralization. This study also validates distinct epitopes for previously reported neutralizing antibodies.

Keywords: Theileria parva; crystal structure; neutralizing; p67; parasite; synthetic antibody.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Characterization of Fab B11. (a) Sequences of Fab B11 CDRs. Only positions that were diversified in the phage‐displayed library are shown and are numbered according to the IMGT nomenclature (Lefranc et al., 2003). (b) Biolayer interferometry (BLI) association and dissociation curves for indicated concentrations of Fab B11 (black) binding to immobilized p67. Binding signals were globally fit (gray) and the calculated K D value is shown. (c) ELISA for binding (y‐axis) of serial dilutions of Fab B11 (x‐axis) to His‐p67C (black squares) and the negative control proteins ubiquitin (white circles) and BSA (white triangles). (d) ELISA for binding (y‐axis) of 50 nM Fab B11 (black), IgG AR21.4 (gray), and IgG AR22.7 (white) to the following antigens (x‐axis): Full‐length p67, p67N (residues 21–225), and p67C (residues 572–651). (e) ELISA for binding (y‐axis) of 50 nM Fab B11 (black) and IgG AR21.4 (gray) to the following antigens (x‐axis): p67C, p671, and p672. (f) Neutralization activity in an in vitro sporozoite neutralization assay with bovine PBMCs. Five‐fold serial dilutions of antibody from 250 nM were evaluated in the sporozoite neutralization assay relative to a non‐binding IgG isotype control. Error bars were derived from the standard deviation of technical replicates run in triplicate and results shown are representative of experiments run in quadruplicate.
FIGURE 2
FIGURE 2
Crystal structure of Fab B11 in complex with p67C1. (a) Fab B11 is shown as a ribbon with the light chain (LC) and heavy chain (HC) colored light or dark gray, respectively, except for the CDRs (as defined by the IMGT nomenclature (Lefranc et al., 2003)), which are colored as follows: L1, (blue), L2 (magenta), L3 (cyan), H1 (yellow), H2 (orange), H3 (red). p67C1a (the 20‐residue region of p67C (Nene & Morrison, 2016) that was resolved in the electron density map) is shown as a green ribbon with the N‐terminus rendered as a sphere. The side and top‐down views of Fab B11 are shown at left and right, respectively.
FIGURE 3
FIGURE 3
Antibodies binding to minimal p67 epitopes. (a) Fab B11 binding to p67 residues 574–598 (biotin‐GGGSLRGLDLSEEEVKKILDEIVKD). (b) IgG AR21.4 binding to p67 residues 612–628 (PSGRSSERQPSLGPSLVGGGSK‐biotin). (c) IgG AR22.7 binding to p67 residues 204–220 (ELKKTLQPGKTSTGETTGGGSK‐biotin). BLI association and dissociation curves (black) are shown for indicated concentrations (black) of antibody binding to immobilized biotinylated peptide. Binding signals were globally fit (gray) and the calculated K D values are shown.
FIGURE 4
FIGURE 4
The functional epitope of p67C1a for binding to Fab B11. (a) Open book view of the p67C1:Fab‐B11 complex. The 20‐residue p67C1a peptide (left) and Fab B11 (right) are shown as transparent surfaces. p67C1a residues are colored red or green if alanine substitutions did or did not reduce binding significantly (Ala/WT >6), respectively, and residues that do not contact Fab B11 are colored gray. Side chains are shown for residues that were hits in the alanine scan. Fab B11 residues are colored red or green if they contact p67C1a residues that were or were not hits in the alanine scan, respectively, and other residues in the light and heavy chains are colored light or dark gray, respectively. Side chains are shown for residues that contact p67C1a residues that were hits in the alanine scan. (b) Details of the molecular interactions between Fab B11 and p67C1a residues (i) G580 and Leu581, (ii) Val588 and Leu592, and (iii) Asp593 and K597. p67C1a residues are colored green. Fab B11 residues are colored as follows: CDR‐L2, (magenta), CDR‐L3 (cyan), CDR‐H1 (yellow), CDR‐H2 (orange), CDR‐H3 (red), framework (gray). Fab B11 side chains that interact with the relevant p67C1a residues are shown, and hydrogen bonds are shown as dashed lines.

Similar articles

References

    1. Adams PD, Grosse‐Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr. 2002;58:1948–1954. - PubMed
    1. Anon . The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994;50:760–763. - PubMed
    1. Anon . Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31–45. - PMC - PubMed
    1. Arnon R, Tarrab‐Hazdai R, Steward M. A mimotope peptide‐based vaccine against Schistosoma mansoni: synthesis and characterization. Immunology. 2000;101:555. - PMC - PubMed
    1. Bartlett S, Eichenberger RM, Nevagi RJ, Ghaffar KA, Marasini N, Dai Y, et al. Lipopeptide‐based Oral vaccine against hookworm infection. J Infect Dis. 2020;221:934–942. - PubMed

MeSH terms